Overview

A Study to Assess the Efficacy and Safety of HMI-115(HMI-115 is the Company Giving Name of This Specific Prolactin Receptor Antibody) in Subjects With Endometriosis

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
Phase:
Phase 2
Details
Lead Sponsor:
Hope Medicine (Nanjing) Co., Ltd